ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Short Interest Down 46.6% in March

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) was the recipient of a large decrease in short interest in the month of March. As of March 13th, there was short interest totaling 5,007 shares, a decrease of 46.6% from the February 26th total of 9,382 shares. Currently, 0.2% of the company’s stock are short sold. Based on an average daily volume of 23,217 shares, the short-interest ratio is presently 0.2 days.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of SBIO. Raymond James Financial Inc. bought a new stake in ALPS Medical Breakthroughs ETF in the 2nd quarter valued at approximately $82,000. Global Retirement Partners LLC acquired a new position in ALPS Medical Breakthroughs ETF during the 4th quarter worth approximately $34,000. Comerica Bank bought a new position in shares of ALPS Medical Breakthroughs ETF during the 3rd quarter worth approximately $27,000. Steward Partners Investment Advisory LLC bought a new position in shares of ALPS Medical Breakthroughs ETF during the 4th quarter worth approximately $26,000. Finally, Virtu Financial LLC grew its stake in shares of ALPS Medical Breakthroughs ETF by 7.3% during the 4th quarter. Virtu Financial LLC now owns 17,967 shares of the company’s stock worth $920,000 after acquiring an additional 1,229 shares in the last quarter.

ALPS Medical Breakthroughs ETF Trading Down 0.2%

SBIO stock opened at $49.90 on Friday. The stock has a 50-day moving average price of $50.95 and a two-hundred day moving average price of $47.20. ALPS Medical Breakthroughs ETF has a 1 year low of $22.33 and a 1 year high of $54.79.

About ALPS Medical Breakthroughs ETF

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.